<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-960
Date of Submission: 2025-06-20

This report was submitted by a Other Healthcare Professional from Brooks Group Medical Center concerning patient ANON-PX-3534. The subject is a 31-year-old female with a significant medical history including seasonal allergies, hypertension. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin (Anticoagulant) administered via the Intravenous route at a dosage of 352mg, initiated on 2025-04-11 for Thromboembolism prevention and discontinued on 2025-06-09; Sertraline administered via the Intramuscular route at a dosage of 267mg, initiated on 2025-04-11 for Major depressive disorder and discontinued on 2025-06-09.

On approximately 2025-04-24, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Anaphylaxis. The Maculopapular Rash was classified as Moderate in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Not Recovered'. The Anaphylaxis was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Else song adult maybe hour.</data>
report_id: ADR-2025-960
report_date: '2025-06-20'
patient_details:
  patient_id: ANON-PX-3534
  gender: Female
  relevant_history:
  - seasonal allergies
  - hypertension
  age_at_reaction: 31
suspected_drugs:
- drug_name: Warfarin
  dosage: 352mg
  route_of_administration: Intravenous
  start_date: '2025-04-11'
  indication_for_use: Thromboembolism prevention
  drug_class: Anticoagulant
  end_date: '2025-06-09'
- drug_name: Sertraline
  dosage: 267mg
  route_of_administration: Intramuscular
  start_date: '2025-04-11'
  indication_for_use: Major depressive disorder
  end_date: '2025-06-09'
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2025-04-24'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: true
- symptom_name: Anaphylaxis
  onset_date: '2025-04-24'
  severity: Severe
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 5
reporting_facility: Brooks Group Medical Center
reporter_type: Other Healthcare Professional
notes: Else song adult maybe hour.
